These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38112806)

  • 1. Wharton's jelly mesenchymal stem cells transplantation for critical limb ischemia in patients with type 2 diabetes mellitus: a preliminary report of phase I clinical trial.
    Ashoobi MT; Hemmati H; Aghayan HR; Zarei-Behjani Z; Keshavarz S; Babaloo H; Maroufizadeh S; Yousefi S; Farzin M; Vojoudi E
    Cell Tissue Res; 2024 Feb; 395(2):211-220. PubMed ID: 38112806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells.
    Arango-Rodríguez ML; Mateus LC; Sossa CL; Becerra-Bayona SM; Solarte-David VA; Ochoa Vera ME; Viviescas LTG; Berrio AMV; Serrano SE; Vargas O; Isla AC; Benitez A; Rangel G
    Stem Cell Res Ther; 2023 Aug; 14(1):221. PubMed ID: 37626416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary evaluation of efficacy and safety of Wharton's jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus.
    Liu X; Zheng P; Wang X; Dai G; Cheng H; Zhang Z; Hua R; Niu X; Shi J; An Y
    Stem Cell Res Ther; 2014 Apr; 5(2):57. PubMed ID: 24759263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI).
    Shirbaghaee Z; Heidari Keshel S; Rasouli M; Valizadeh M; Hashemi Nazari SS; Hassani M; Soleimani M
    Stem Cell Res Ther; 2023 Jul; 14(1):174. PubMed ID: 37408043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regenerative Potential of the Product "CardioCell" Derived from the Wharton's Jelly Mesenchymal Stem Cells for Treating Hindlimb Ischemia.
    Musiał-Wysocka A; Kot M; Sułkowski M; Majka M
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of retinitis pigmentosa by Wharton's jelly derived mesenchymal stem cells: preliminary clinical results.
    Özmert E; Arslan U
    Stem Cell Res Ther; 2020 Jan; 11(1):25. PubMed ID: 31931872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and clinical applications of Wharton's jelly-derived mesenchymal stromal cells.
    Liau LL; Ruszymah BHI; Ng MH; Law JX
    Curr Res Transl Med; 2020 Jan; 68(1):5-16. PubMed ID: 31543433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of 2 Intracavernous Injections of Allogeneic Wharton's Jelly-Derived Mesenchymal Stem Cells in Diabetic Patients with Erectile Dysfunction: Phase 1/2 Clinical Trial.
    Al Demour S; Adwan S; Jafar H; Rahmeh R; Alhawari H; Awidi A
    Urol Int; 2021; 105(11-12):935-943. PubMed ID: 34384079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single high-dose intravenous injection of Wharton's jelly-derived mesenchymal stem cell exerts protective effects in a rat model of metabolic syndrome.
    Chan AML; Ng AMH; Yunus MHM; Idrus RH; Law JX; Yazid MD; Chin KY; Yusof MRM; Ng SN; Koh B; Lokanathan Y
    Stem Cell Res Ther; 2024 Jun; 15(1):160. PubMed ID: 38835014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells.
    Batsali AK; Pontikoglou C; Koutroulakis D; Pavlaki KI; Damianaki A; Mavroudi I; Alpantaki K; Kouvidi E; Kontakis G; Papadaki HA
    Stem Cell Res Ther; 2017 Apr; 8(1):102. PubMed ID: 28446235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone Marrow and Wharton's Jelly Mesenchymal Stromal Cells are Ineffective for Myocardial Repair in an Immunodeficient Rat Model of Chronic Ischemic Cardiomyopathy.
    Tang XL; Nasr M; Zheng S; Zoubul T; Stephan JK; Uchida S; Singhal R; Khan A; Gumpert A; Bolli R; Wysoczynski M
    Stem Cell Rev Rep; 2023 Oct; 19(7):2429-2446. PubMed ID: 37500831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal Stem Cells: Case Report of an Adjuvant Ambulatory Therapy for a COVID-19 High-Risk and Steroid-hypersensitive Patients.
    Cardoso-Hernández GA; Camacho-Torres AL; Camacho-Pérez B; González Sánchez FA; Navarro-Partida J; García-Varela R; Aguilar-Aguilar J; Aguilar Alemán JP
    Curr Stem Cell Res Ther; 2023; 18(7):1016-1025. PubMed ID: 36043767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy.
    Nammian P; Asadi-Yousefabad SL; Daneshi S; Sheikhha MH; Tabei SMB; Razban V
    Stem Cell Res Ther; 2021 Jan; 12(1):58. PubMed ID: 33436054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect and mechanisms of human Wharton's jelly-derived mesenchymal stem cells on type 1 diabetes in NOD model.
    Hu J; Wang Y; Wang F; Wang L; Yu X; Sun R; Wang Z; Wang L; Gao H; Fu Z; Zhao W; Yan S
    Endocrine; 2015 Feb; 48(1):124-34. PubMed ID: 24590294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of anti-fibrotic factors ameliorates anti-fibrotic properties of Wharton's jelly derived mesenchymal stem cells under oxidative damage.
    Nimsanor N; Phetfong J; Kitiyanant N; Kamprom W; Supokawej A
    Biosci Trends; 2019 Nov; 13(5):411-422. PubMed ID: 31656260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal Stem Cells from Wharton's Jelly and Amniotic Fluid.
    Joerger-Messerli MS; Marx C; Oppliger B; Mueller M; Surbek DV; Schoeberlein A
    Best Pract Res Clin Obstet Gynaecol; 2016 Feb; 31():30-44. PubMed ID: 26482184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wharton's jelly-derived mesenchymal stem cells attenuate sepsis-induced organ injury partially via cholinergic anti-inflammatory pathway activation.
    Capcha JMC; Rodrigues CE; Moreira RS; Silveira MD; Dourado P; Dos Santos F; Irigoyen MC; Jensen L; Garnica MR; Noronha IL; Andrade L; Gomes SA
    Am J Physiol Regul Integr Comp Physiol; 2020 Jan; 318(1):R135-R147. PubMed ID: 31596111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Fe
    Li X; Wei Z; Wu L; Lv H; Zhang Y; Li J; Yao H; Zhang H; Yang B; Xu X; Jiang J
    Biomater Sci; 2020 Oct; 8(19):5362-5375. PubMed ID: 32869785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human chorionic-plate-derived mesenchymal stem cells and Wharton's jelly-derived mesenchymal stem cells: a comparative analysis of their potential as placenta-derived stem cells.
    Kim MJ; Shin KS; Jeon JH; Lee DR; Shim SH; Kim JK; Cha DH; Yoon TK; Kim GJ
    Cell Tissue Res; 2011 Oct; 346(1):53-64. PubMed ID: 21987220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wharton's jelly-derived stromal cells and their cell therapy applications in allogeneic haematopoietic stem cell transplantation.
    Pochon C; Notarantonio AB; Laroye C; Reppel L; Bensoussan D; Bertrand A; Rubio MT; D'Aveni M
    J Cell Mol Med; 2022 Mar; 26(5):1339-1350. PubMed ID: 35088933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.